The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis

Published:2020-01-01 Issue:1 Volume:25 Page:414-423
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Guo Yuancheng¹^ORCID,Liu Bei¹,Deng Lijuan¹,Qiao Yanhong²,Jian Jinli¹

Affiliation:

1. The First Clinical Medical College, Lanzhou University, Lanzhou, People’s Republic of China

2. Department of Haematology, Xi'an Central Hospital, Xi’an, Shaanxi, China

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2020.1843752

Reference22 articles.

1. Acute myeloid leukemia in the older adults

2. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome:

3. BCL-2 family antagonists for cancer therapy

4. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

5. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with RUNX1 mutation;Hematology;2024-08-20

2. Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies;Discover Oncology;2024-07-26

3. MDS and AML show elevated fractions of CD34-positive blast cell populations with a high anti-apoptotic versus proliferation ratio;Leukemia Research;2024-07

4. Venetoclax adverse event monitoring: a safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS;Annals of Hematology;2024-02-26

5. Blastic Plasmacytoid Dendritic Cell Neoplasm in Long-Term Complete Remission After Venetoclax Monotherapy;Cureus;2024-01-17